亚洲IVF/ICSI人群中促卵泡激素δ个体化固定剂量方案的随机对照试验
该多中心随机对照试验纳入1009例亚洲首次IVF/ICSI患者,比较基于AMH和体重的个体化固定剂量促卵泡激素δ与常规剂量促卵泡激素α。结果显示,促卵泡激素δ组持续妊娠率非劣于促卵泡激素α组,活产率显著更高,早发型卵巢过度刺激综合征(OHSS)和/或预防干预发生率显著更低,且促性腺激素总用量更少。
要点
- 促卵泡激素δ个体化固定剂量组的持续妊娠率为31.3%,非劣于促卵泡激素α组的25.7%。
- 促卵泡激素δ组活产率显著高于促卵泡激素α组(31.3% vs 24.7%,P=0.023)。
- 促卵泡激素δ组早发型OHSS和/或预防干预发生率显著低于促卵泡激素α组(5.0% vs 9.6%,P=0.004)。
核心结论
- 在亚洲首次IVF/ICSI患者中,基于AMH和体重的促卵泡激素δ个体化固定剂量方案的持续妊娠率非劣于常规剂量促卵泡激素α,且活产率更高、早发型OHSS风险更低、促性腺激素用量更少。
研究设计与样本
- 随机、对照、多中心、评估者盲法试验,纳入来自中国大陆、韩国、越南和台湾的1009例首次IVF/ICSI的亚洲患者,按年龄(<35、35-37、38-40岁)分层随机。
- 促卵泡激素δ组根据初始AMH水平和体重给予固定每日剂量(AMH<15 pmol/l:12 μg;AMH≥15 pmol/l:0.19至0.10 μg/kg;最小-最大6-12 μg)。
- 促卵泡激素α组前5天每日150 IU,随后根据个体反应调整剂量;采用GnRH拮抗剂方案。
- 主要终点为新鲜周期胚胎移植后10-11周的持续妊娠率,非劣效界值为-10.0%,分析按年龄分层调整。
主要发现
- 促卵泡激素δ组获卵数显著低于促卵泡激素α组(10.0±6.1 vs 12.4±7.3,P<0.001)。
- 在AMH<15 pmol/l的可能低反应者中,促卵泡激素δ组平均获卵数多2枚(9.6±5.3 vs 7.6±3.5);在AMH≥15 pmol/l的可能高反应者中,平均获卵数少3枚(10.1±6.3 vs 13.8±7.5)。
- 在AMH≥15 pmol/l的女性中,促卵泡激素δ组过度反应(≥15卵:20.2% vs 39.1%;≥20卵:6.7% vs 18.5%;均P<0.001)发生率低于促卵泡激素α组。
- 促卵泡激素δ组早发型OHSS和/或预防干预发生率从促卵泡激素α组的9.6%显著降至5.0%(P=0.004)。
- 促卵泡激素δ组促性腺激素总用量显著减少(77.5±24.4 μg vs 109.9±32.9 μg(1498±448 IU),P<0.001)。
关键数值与推荐
- 促卵泡激素δ个体化固定剂量:AMH<15 pmol/l时每日12 μg;AMH≥15 pmol/l时0.19至0.10 μg/kg,最小-最大6-12 μg。
- 促卵泡激素α常规剂量:前5天每日150 IU,之后根据个体反应调整。
- 主要终点非劣效界值为-10.0%,持续妊娠率估计平均差异5.4%(95%CI:-0.2%;11.0%)。
- 活产率估计平均差异6.4%(95%CI:0.9%;11.9%),P=0.023。
- 早发型OHSS和/或预防干预发生率:促卵泡激素δ组5.0%,促卵泡激素α组9.6%,P=0.004。
临床怎么用
- 对于亚洲首次IVF/ICSI患者,可考虑基于AMH和体重的促卵泡激素δ个体化固定剂量方案,以降低OHSS风险并可能提高活产率。
- 该方案可减少促性腺激素总用量,并根据AMH水平调节卵巢反应:低反应者获卵数增加,高反应者获卵数减少。
- 研究结果仅适用于新鲜 cleavage-stage 胚胎移植的一个治疗周期,临床决策需结合患者个体情况。
局限性
- 试验仅涵盖一个治疗周期的新鲜 cleavage-stage 胚胎移植的临床结局。
- 研究由Ferring Pharmaceuticals资助,部分作者为该公司雇员或持有相关专利。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Is ovarian stimulation with follitropin delta in its individualised fixed-dose regimen at least as efficacious as follitropin alfa in a conventional dosing regimen in Asian population? SUMMARY ANSWER: Ovarian stimulation with individualised follitropin delta dosing resulted in a non-inferior ongoing pregnancy rate, a significantly higher live birth rate and a significantly lower incidence of early ovarian hyperstimulation syndrome (OHSS) and/or preventive interventions compared to conventional follitropin alfa dosing. WHAT IS KNOWN ALREADY: Previous randomised controlled trials conducted in Japan as well as in Europe, North- and South America have demonstrated that ovarian stimulation with the individualised follitropin delta dosing regimen based on serum anti-Müllerian hormone (AMH) level and body weight modulated the ovarian response and reduced the risk of OHSS without compromising pregnancy and live birth rates. STUDY DESIGN, SIZE, DURATION: Randomised, controlled, multi-centre, assessor-blind trial conducted in 1009 Asian patients from mainland China, South Korea, Vietnam and Taiwan, undergoing their first IVF/ICSI cycle. Randomisation was stratified by age (<35, 35-37, 38-40 years). The primary endpoint was ongoing pregnancy rate assessed 10-11 weeks after embryo transfer in the fresh cycle (non-inferiority limit -10.0%; analysis adjusted for age stratum). PARTICIPANTS/MATERIALS, SETTING, METHODS: The follitropin delta treatment consisted of a fixed daily dose individualised according to each patient's initial AMH level and body weight (AMH <15 pmol/l: 12 μg; AMH ≥15 pmol/l: 0.19 to 0.10 μg/kg; min-max 6-12 μg). The follitropin alfa dose was 150 IU/day for the first 5 days with subsequent potential dose adjustments according to individual response. A GnRH antagonist protocol was applied. OHSS was classified based on Golan's system. Women with an ongoing pregnancy were followed until live birth and 4 weeks after. MAIN RESULTS AND THE ROLE OF CHANCE: The number of oocytes retrieved was significantly (P < 0.001) lower with individualised follitropin delta versus conventional follitropin alfa (10.0 ± 6.1 versus 12.4 ± 7.3). Nevertheless, compared to the conventional dosing approach, the individualised follitropin delta dosing regimen resulted in on average 2 more oocytes (9.6 ± 5.3 versus 7.6 ± 3.5) in potential low responders as indicated by AMH <15 pmol/l, and on average 3 fewer oocytes (10.1 ± 6.3 versus 13.8 ± 7.5) in potential high responders as indicated by AMH ≥15 pmol/l. Among women with AMH ≥15 pmol/l, excessive response occurred less frequently with individualised follitropin delta than with follitropin alfa (≥15 oocytes: 20.2% versus 39.1%; ≥20 oocytes: 6.7% versus 18.5%; both P < 0.001). The incidence of early OHSS and/or preventive interventions for early OHSS was significantly (P = 0.004) reduced from 9.6% with follitropin alfa to 5.0% with individualised follitropin delta. The total gonadotropin use was significantly (P < 0.001) reduced from an average of 109.9 ± 32.9 μg (1498 ± 448 IU) follitropin alfa to 77.5 ± 24.4 μg follitropin delta. Non-inferiority of follitropin delta in its individualised dosing regimen to conventional follitropin alfa was established with respect to the primary endpoint of ongoing pregnancy rate which was 31.3% with follitropin delta compared to 25.7% with follitropin alfa (estimated mean difference 5.4% [95% CI: -0.2%; 11.0%]). The live birth rate was significantly higher at 31.3% with individualised follitropin delta compared to 24.7% with follitropin alfa (estimated mean difference 6.4% [95% CI: 0.9%; 11.9%]; P = 0.023). The live birth rate for each stratum were as follows for follitropin delta and follitropin alfa, respectively; <35 years: 31.0% versus 25.0%, 35-37 years: 35.3% versus 26.7%, 38-40 years: 20.0% versus 14.3%. LIMITATIONS, REASONS FOR CAUTION: The trial only covered the clinical outcome of one treatment cycle with fresh cleavage-stage embryo transfers. WIDER IMPLICATIONS OF THE FINDINGS: The present trial shows that in addition to reducing the early OHSS risk, follitropin delta in its individualised fixed-dose regimen has the potential to improve the success rate in fresh cycles across all ages and with a lower gonadotropin consumption compared to conventional follitropin alfa dosing. STUDY FUNDING/COMPETING INTEREST(S): This study was funded by Ferring Pharmaceuticals. J.Q., Y.Z., X.L., T.H., H.-Y.H. and S.-H.K. have received institutional (not personal) clinical trial fees from Ferring Pharmaceuticals. M.G., B.M. and J.-C.A. are employees of Ferring Pharmaceuticals. J.-C.A. has pending and issued patent applications in the WO 2013/020996 and WO 2019/043143 patent families that comprise allowed and granted patent rights related to follitropin delta. TRIAL REGISTRATION NUMBER: NCT03296527 (clinicaltrials.gov). TRIAL REGISTRATION DATE: 28 September 2017. DATE OF FIRST PATIENT’S ENROLMENT: 1 December 2017.
引用
- Qiao J, Zhang Y, Liang X, et al. A randomised controlled trial to clinically validate follitropin delta in its individualised dosing regimen for ovarian stimulation in Asian IVF/ICSI patients. Hum Reprod. 2021. PMID: 34179971. doi:10.1093/humrep/deab155
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。